(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.Choi, H.S., Rucker, P.V., Wang, Z., Fan, Y., Albaugh, P., Chopiuk, G., Gessier, F., Sun, F., Adrian, F., Liu, G., Hood, T., Li, N., Jia, Y., Che, J., McCormack, S., Li, A., Li, J., Steffy, A., Culazzo, A., Tompkins, C., Phung, V., Kreusch, A., Lu, M., Hu, B., Chaudhary, A., Prashad, M., Tuntland, T., Liu, B., Harris, J., Seidel, H.M., Loren, J., Molteni, V.
(2015) ACS Med Chem Lett 6: 562-567
- PubMed: 26005534
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00050
- Primary Citation of Related Structures:
4YMJ, 4YNE, 4YPS
- PubMed Abstract:
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors. By screening the Novartis compound collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization. Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts. From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.
Genomics Institute of the Novartis Research Foundation , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.